{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:23:17Z","timestamp":1791285797880,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1038\/bjc.2016.26","type":"journal-article","created":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T23:46:12Z","timestamp":1458258372000},"page":"759-766","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Hexokinase 2 is a determinant of neuroblastoma metastasis"],"prefix":"10.1038","volume":"114","author":[{"given":"Liat","family":"Edry Botzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Maman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Sagi-Assif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsipi","family":"Meshel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ido","family":"Nevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Yron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac P","family":"Witz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,17]]},"reference":[{"issue":"1","key":"BFbjc201626_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10930-004-0600-2","volume":"24","author":"JA Al jamal","year":"2005","unstructured":"Al jamal JA (2005) Involvement of porin N,N-dicyclohexylcarbodiimide-reactive domain in hexokinase binding to the outer mitochondrial membrane. Protein J 24 (1): 1\u20138.","journal-title":"Protein J"},{"issue":"6","key":"BFbjc201626_CR2","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.ygeno.2004.08.010","volume":"84","author":"B Altenberg","year":"2004","unstructured":"Altenberg B, Greulich KO (2004) Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84 (6): 1014\u20131020.","journal-title":"Genomics"},{"issue":"2","key":"BFbjc201626_CR3","first-page":"217","volume":"72","author":"D Balinsky","year":"1984","unstructured":"Balinsky D, Platz CE, Lewis JW (1984) Enzyme activities in normal, dysplastic, and cancerous human breast tissues. J Natl Cancer Inst 72 (2): 217\u2013224.","journal-title":"J Natl Cancer Inst"},{"issue":"11 Pt 1","key":"BFbjc201626_CR4","first-page":"3751","volume":"38","author":"JL Biedler","year":"1978","unstructured":"Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38 (11 Pt 1): 3751\u20133757.","journal-title":"Cancer Res"},{"issue":"8","key":"BFbjc201626_CR5","first-page":"E73","volume":"93","author":"C Brahimi-Horn","year":"2006","unstructured":"Brahimi-Horn C, Pouyssegur J (2006) The role of the hypoxia-inducible factor in tumor metabolism growth and invasion. Bull Cancer 93 (8): E73\u2013E80.","journal-title":"Bull Cancer"},{"issue":"2","key":"BFbjc201626_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10637-008-9145-0","volume":"27","author":"M Buijs","year":"2009","unstructured":"Buijs M, Vossen JA, Geschwind JFH, Ishimori T, Engles JM, Acha-Ngwodo O, Wahl RL, Vali M (2009) Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest New Drug 27 (2): 120\u2013123.","journal-title":"Invest New Drug"},{"issue":"8","key":"BFbjc201626_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrc865","volume":"2","author":"AF Chambers","year":"2002","unstructured":"Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2 (8): 563\u2013572.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"BFbjc201626_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.bbabio.2009.03.003","volume":"1787","author":"Z Chen","year":"2009","unstructured":"Chen Z, Zhang H, Lu WQ, Huang P (2009) Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim Biophys Acta 1787 (5): 553\u2013560.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"BFbjc201626_CR9","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ajpath.2011.03.020","volume":"179","author":"L Edry Botzer","year":"2011","unstructured":"Edry Botzer L, Maman S, Sagi-Assif O, Meshel T, Nevo I, B\u00e4uerle T, Yron I, Witz IP (2011) Lung-residing metastatic and dormant neuroblastoma cells. Am J Pathol 179 (1): 524\u2013536.","journal-title":"Am J Pathol"},{"key":"BFbjc201626_CR10","doi-asserted-by":"publisher","first-page":"878709","DOI":"10.1155\/2010\/878709","volume":"2010","author":"P Fardin","year":"2010","unstructured":"Fardin P, Cornero A, Barla A, Mosci S, Acquaviva M, Rosasco L, Gambini C, Verri A, Varesio L (2010) Identification of multiple hypoxia signatures in neuroblastoma cell lines by l(1)-l(2) regularization and data reduction. J Biomed Biotechnol 2010: 878709.","journal-title":"J Biomed Biotechnol"},{"issue":"4","key":"BFbjc201626_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.cell.2006.11.001","volume":"127","author":"GP Gupta","year":"2006","unstructured":"Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127 (4): 679\u2013695.","journal-title":"Cell"},{"issue":"1","key":"BFbjc201626_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/ki.2010.112","volume":"78","author":"VH Haase","year":"2010","unstructured":"Haase VH (2010) The sweet side of HIF. Kidney Int 78 (1): 10\u201313.","journal-title":"Kidney Int"},{"issue":"5","key":"BFbjc201626_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144 (5): 646\u2013674.","journal-title":"Cell"},{"issue":"9","key":"BFbjc201626_CR14","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1158\/1535-7163.MCT-07-0115","volume":"6","author":"W Kim","year":"2007","unstructured":"Kim W, Yoon JH, Jeong JM, Cheon GJ, Lee TS, Yang JI, Park SC, Lee HS (2007) Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol Cancer Ther 6 (9): 2554\u20132562.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"BFbjc201626_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.canlet.2013.08.029","volume":"352","author":"A Klein-Goldberg","year":"2014","unstructured":"Klein-Goldberg A, Maman S, Witz IP (2014) The role played by the microenvironment in site-specific metastasis. Cancer Lett 352 (1): 54\u201358.","journal-title":"Cancer Lett"},{"issue":"1","key":"BFbjc201626_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0304-3835(01)00667-X","volume":"173","author":"YH Ko","year":"2001","unstructured":"Ko YH, Pedersen PL, Geschwind JF (2001) Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173 (1): 83\u201391.","journal-title":"Cancer Lett"},{"key":"BFbjc201626_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/1158415-S0-000000000-00000","volume":"30","author":"A Levy","year":"2010","unstructured":"Levy A, Zage P, Akers L, Ghisoli M, Chen Z, Fang W, Kannan S, Graham T, Zeng L, Franklin A, Huang P, Zweidler-McKay P (2010) The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma. Invest New Drug 30: 1\u20139.","journal-title":"Invest New Drug"},{"issue":"10","key":"BFbjc201626_CR18","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1002\/ijc.28255","volume":"133","author":"S Maman","year":"2013","unstructured":"Maman S, Edry-Botzer L, Sagi-Assif O, Meshel T, Yuan W, Lu W, Witz IP (2013) The metastatic microenvironment: lung-derived factors control the viability of neuroblastoma lung metastasis. Int J Cancer 133 (10): 2296\u20132306.","journal-title":"Int J Cancer"},{"key":"BFbjc201626_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-94-007-6217-6_2","volume-title":"The Tumor Immunoenvironment","author":"S Maman","year":"2013","unstructured":"Maman S, Witz IP (2013) The metastatic microenvironment. In The Tumor Immunoenvironment, Shurin MR, Umansky V, Malyguine A (eds), Vol. XVI, pp 15\u201338. Springer: New York, NY."},{"issue":"9","key":"BFbjc201626_CR20","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2174\/138955709788922610","volume":"9","author":"A Marin-Hernandez","year":"2009","unstructured":"Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R (2009) HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 9 (9): 1084\u20131101.","journal-title":"Mini Rev Med Chem"},{"issue":"9","key":"BFbjc201626_CR21","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1111\/j.1742-4658.2006.05214.x","volume":"273","author":"A Marin-Hernandez","year":"2006","unstructured":"Marin-Hernandez A, Rodriguez-Enriquez S, Vital-Gonzalez PA, Flores-Rodriguez FL, Macias-Silva M, Sosa-Garrocho M, Moreno-Sanchez R (2006) Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase. FEBS J 273 (9): 1975\u20131988.","journal-title":"FEBS J"},{"issue":"9579","key":"BFbjc201626_CR22","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","volume":"369","author":"JM Maris","year":"2007","unstructured":"Maris JM, Hogarty MD, Bagatell R, Cohn SL (2007) Neuroblastoma. Lancet 369 (9579): 2106\u20132120.","journal-title":"Lancet"},{"issue":"36","key":"BFbjc201626_CR23","doi-asserted-by":"publisher","first-page":"22776","DOI":"10.1074\/jbc.272.36.22776","volume":"272","author":"SP Mathupala","year":"1997","unstructured":"Mathupala SP, Heese C, Pedersen PL (1997) Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem 272 (36): 22776\u201322780.","journal-title":"J Biol Chem"},{"issue":"1","key":"BFbjc201626_CR24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.semcancer.2008.11.006","volume":"19","author":"SP Mathupala","year":"2009","unstructured":"Mathupala SP, Ko YH, Pedersen PL (2009) Hexokinase-2 bound to mitochondria: cancer's stygian link to the \"Warburg Effect\" and a pivotal target for effective therapy. Semin Cancer Biol 19 (1): 17\u201324.","journal-title":"Semin Cancer Biol"},{"issue":"28","key":"BFbjc201626_CR25","doi-asserted-by":"publisher","first-page":"16918","DOI":"10.1074\/jbc.270.28.16918","volume":"270","author":"SP Mathupala","year":"1995","unstructured":"Mathupala SP, Rempel A, Pedersen PL (1995) Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem 270 (28): 16918\u201316925.","journal-title":"J Biol Chem"},{"issue":"46","key":"BFbjc201626_CR26","doi-asserted-by":"publisher","first-page":"43407","DOI":"10.1074\/jbc.M108181200","volume":"276","author":"SP Mathupala","year":"2001","unstructured":"Mathupala SP, Rempel A, Pedersen PL (2001) Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 276 (46): 43407\u201343412.","journal-title":"J Biol Chem"},{"issue":"14","key":"BFbjc201626_CR27","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.2174\/092986709788186192","volume":"16","author":"A Mazzocca","year":"2009","unstructured":"Mazzocca A, Carloni V (2009) The metastatic process: methodological advances and pharmacological challenges. Curr Med Chem 16 (14): 1704\u20131717.","journal-title":"Curr Med Chem"},{"issue":"4","key":"BFbjc201626_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ctrv.2010.02.006","volume":"36","author":"S Modak","year":"2010","unstructured":"Modak S, Cheung NKV (2010) Neuroblastoma: therapeutic strategies for a clinical enigma. Cancer Treat Rev 36 (4): 307\u2013317.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"BFbjc201626_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/adc.2008.143909","volume":"94","author":"D Mullassery","year":"2009","unstructured":"Mullassery D, Dominici C, Jesudason EC, McDowell HP, Losty PD (2009) Neuroblastoma: contemporary management. Arch Dis Child Educ Pract Ed 94 (6): 177\u2013185.","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"7","key":"BFbjc201626_CR30","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/ijc.24889","volume":"126","author":"I Nevo","year":"2010","unstructured":"Nevo I, Oberthuer A, Botzer E, Sagi-Assif O, Maman S, Pasmanik-Chor M, Kariv N, Fischer M, Yron I, Witz IP (2010) Gene-expression-based analysis of local and metastatic neuroblastoma variants reveals a set of genes associated with tumor progression in neuroblastoma patients. Int J Cancer 126 (7): 1570\u20131581.","journal-title":"Int J Cancer"},{"issue":"8","key":"BFbjc201626_CR31","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1593\/neo.08402","volume":"10","author":"I Nevo","year":"2008","unstructured":"Nevo I, Sagi-Assif O, Edry Botzer L, Amar D, Maman S, Kariv N, Leider-Trejo LE, Savelyeva L, Schwab M, Yron I, Witz IP (2008) Generation and characterization of novel local and metastatic human neuroblastoma variants. Neoplasia 10 (8): 816\u2013827.","journal-title":"Neoplasia"},{"issue":"4","key":"BFbjc201626_CR32","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nrc2622","volume":"9","author":"DX Nguyen","year":"2009","unstructured":"Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9 (4): 274\u2013284.","journal-title":"Nat Rev Cancer"},{"issue":"31","key":"BFbjc201626_CR33","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1200\/JCO.2006.06.1879","volume":"24","author":"A Oberthuer","year":"2006","unstructured":"Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, Konig R, Haas S, Eils R, Schwab M, Brors B, Westermann F, Fischer M (2006) Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 24 (31): 5070\u20135078.","journal-title":"J Clin Oncol"},{"issue":"2","key":"BFbjc201626_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1349-7006.2007.00683.x","volume":"99","author":"B Paudyal","year":"2008","unstructured":"Paudyal B, Oriuchi N, Paudyal P, Higuchi T, Nakajima T, Endo K (2008) Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [F-18]-2-fluro-2-deoxy-D-glucose positron emission tomography. Cancer Sci 99 (2): 260\u2013266.","journal-title":"Cancer Sci"},{"issue":"1-3","key":"BFbjc201626_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S0005-2728(02)00248-7","volume":"1555","author":"PL Pedersen","year":"2002","unstructured":"Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH (2002) Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 1555 (1-3): 14\u201320.","journal-title":"Biochim Biophys Acta"},{"issue":"90","key":"BFbjc201626_CR36","first-page":"355","volume":"56","author":"Q Peng","year":"2009","unstructured":"Peng Q, Zhou J, Zhou Q, Pan F, Zhong D, Liang H (2009) Silencing hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Hepatogastroenterology 56 (90): 355\u2013360.","journal-title":"Hepatogastroenterology"},{"issue":"7","key":"BFbjc201626_CR37","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.4161\/cbt.7.7.6199","volume":"7","author":"Q Peng","year":"2008","unstructured":"Peng Q, Zhou Q, Zhou J, Zhong D, Pan F, Liang H (2008a) Stable RNA interference of hexokinase II gene inhibits human colon cancer LoVo cell growth in vitro and in vivo. Cancer Biol Ther 7 (7): 1128\u20131135.","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"BFbjc201626_CR38","first-page":"1045","volume":"19","author":"SY Peng","year":"2008","unstructured":"Peng SY, Lai PL, Pan HW, Hsiao LP, Hsu HC (2008b) Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep 19 (4): 1045\u20131053.","journal-title":"Oncol Rep"},{"issue":"6","key":"BFbjc201626_CR39","first-page":"1329","volume":"8","author":"T Pietsch","year":"1988","unstructured":"Pietsch T, Gottert E, Meese E, Blin N, Feickert HJ, Riehm H, Kovacs G (1988) Characterization of a continuous cell line (MHH-NB-11) derived from advanced neuroblastoma. Anticancer Res 8 (6): 1329\u20131333.","journal-title":"Anticancer Res"},{"issue":"3","key":"BFbjc201626_CR40","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/0006-291X(82)90613-1","volume":"107","author":"PG Polakis","year":"1982","unstructured":"Polakis PG, Wilson JE (1982) Purification of highly bindable rat brain hexokinase by high performance liquid chromatography (HPLC). Biochem Biophys Res Commun 107 (3): 937\u2013943.","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"BFbjc201626_CR41","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1038\/onc.2009.448","volume":"29","author":"LA Pradelli","year":"2010","unstructured":"Pradelli LA, Beneteau M, Chauvin C, Jacquin MA, Marchetti S, Munoz-Pinedo C, Auberger P, Pende M, Ricci JE (2010) Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 29 (11): 1641\u20131652.","journal-title":"Oncogene"},{"issue":"2","key":"BFbjc201626_CR42","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.bbrc.2010.04.126","volume":"396","author":"JZ Qin","year":"2010","unstructured":"Qin JZ, Xin H, Nickoloff BJ (2010) 3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines. Biochem Biophys Res Commun 396 (2): 495\u2013500.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFbjc201626_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1479-5876-9-19","volume":"9","author":"M Sanchez-Arago","year":"2011","unstructured":"Sanchez-Arago M, Cuezva JM (2011) The bioenergetic signature of isogenic colon cancer cells predicts the cell death response to treatment with 3-bromopyruvate, iodoacetate or 5-fluorouracil. J Transl Med 9: 19.","journal-title":"J Transl Med"},{"issue":"10","key":"BFbjc201626_CR44","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nrc3125","volume":"11","author":"N Sethi","year":"2011","unstructured":"Sethi N, Kang Y (2011) Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer 11 (10): 735\u2013748.","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"BFbjc201626_CR45","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2174\/092986709788186255","volume":"16","author":"H Sheng","year":"2009","unstructured":"Sheng H, Niu B, Sun H (2009) Metabolic targeting of cancers: from molecular mechanisms to therapeutic strategies. Curr Med Chem 16 (13): 1561\u20131587.","journal-title":"Curr Med Chem"},{"issue":"1","key":"BFbjc201626_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2174\/1566524033361645","volume":"3","author":"M Stubbs","year":"2003","unstructured":"Stubbs M, Bashford CL, Griffiths JR (2003) Understanding the tumor metabolic phenotype in the genomic era. Curr Mol Med 3 (1): 49\u201359.","journal-title":"Curr Mol Med"},{"issue":"3","key":"BFbjc201626_CR47","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1023\/A:1022939318102","volume":"20","author":"P Subarsky","year":"2003","unstructured":"Subarsky P, Hill RP (2003) The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 20 (3): 237\u2013250.","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"BFbjc201626_CR48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jvir.2006.10.019","volume":"18","author":"M Vali","year":"2007","unstructured":"Vali M, Liapi E, Kowalski J, Hong K, Khwaja A, Torbenson MS, Georgiades C, Geschwind JFH (2007) Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): Identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol 18 (1): 95\u2013102.","journal-title":"J Vasc Interv Radiol"},{"issue":"3191","key":"BFbjc201626_CR49","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg O (1956) On the origin of cancer cells. Science 123 (3191): 309\u2013314.","journal-title":"Science"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201626.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201626","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201626.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T02:36:44Z","timestamp":1718419004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["BFbjc201626"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2016.26","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"4 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}